American College of Cardiology publishes case study demonstrating clinical utility of PULS Cardiac Test

CCTA confirms Coronary Artery Disease first detected in 46-year old veteran by biomarker-based blood test

Irvine, California-based Global Discovery Biosciences (GD Biosciences) announced the American College of Cardiology published a patient case study online as part of the Diabetes and Cardiometabolic Disease Clinical Topic Collection demonstrating the detection of sub-clinical coronary artery disease (CAD) in a 46 year old male.

Heart disease remains the leading cause of death and disability in the U.S. despite recent improvements in disease management. The PULS Cardiac Test has received significant attention within the medical community as an effective diagnostic tool that allows physicians to identify patients with subclinical, asymptomatic heart disease, who may otherwise be unaware they are at risk of experiencing an acute cardiac event.

Such was the case with a young, 46-year old veteran who, during a pre-retirement medical evaluation, only reported slight chest pain from a previous war injury. Although all of his conventional cardiac evaluation tests including a stress test were normal, his PULS Cardiac test indicated the patient’s risk of a heart attack was five times the expected for his age and gender group. A subsequent coronary computed tomography angiogram (CCTA) was performed and identified a non-obstructive left anterior descending coronary artery (LAD) lesion with a thin cap necrotic core (vulnerable plaque).

The patient was given pre-op cardiac medications and was scheduled for elective angioplasty. Unfortunately, the patient neglected to start his medications and had a heart attack prior to the angioplasty. Luckily, because he was aware of his condition, he was rapidly transported to the hospital where a rescue stent provided successful re-vascularization and an excellent recovery.

“This is the first case where I informed the patient that he would most likely have a heart attack if we do not intervene. The PULS Cardiac Test played an important role in improving patient care.” commented Dr. Eric Harrison, M.D., FACC.

The PULS Cardiac Test is a blood test that measures the 9 protein biomarkers of the body’s immune response to arterial injury leading to formation of cardiac lesions which can become unstable and might rupture causing a blood clot leading to a heart attack. Unstable lesion rupture is the most common cause of heart attacks (75%), not narrowing of the arteries as is commonly believed.

“The PULS Cardiac Test is unlike any other test because it was developed to detect the body’s immune system response to arterial or endothelial damage,” said Douglas S. Harrington, M.D., CEO of GD Biosciences. “This allows physicians to better identify the cardiac disease stage and improve patient care.”

> Click here to view the published Case Study

twttr.conversion.trackPid(‘nugcf’, { tw_sale_amount: 0, tw_order_quantity: 0 });